Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Velusetrag (Primary)
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Therapeutic Use
- Acronyms DIGEST
- Sponsors Theravance Biopharma
- 02 Aug 2017 Primary endpoint (7-day mean GCSI-24H composite score (Gastroparesis Cardinal Symptoms Index) has been met.
- 02 Aug 2017 According to Theravance Biopharma media release, company intends to present additional results from the study at upcoming medical conferences, as well as in appropriate scientific journals.
- 02 Aug 2017 Results published in a Theravance Biopharma media release.